West Bourne is a technology company.
West Bourne has raised $530K across 1 funding round.
West Bourne has raised $530K in total across 1 funding round.
West Bourne has raised $530K in total across 1 funding round.
West Bourne's investors include SOSV.
Westbourne IT Global Services (westbourneit.com) is a technology services company specializing in technical and scientific support solutions, with a strong emphasis on the pharmaceutical industry. It provides tailored offerings like global service desks, pharma digital transformation, lab/manufacturing support, on-site ICT, validation services (including CSV/CSA and equipment/process validation), and integration with the ValGenesis product suite for validation and lifecycle management[1][2]. Operating trans-globally with delivery centers in Ireland, New Zealand, and the USA, it employs around 75 people, generates approximately $21.3 million in revenue, and boasts over 30 years of client engagement, focusing on highly skilled, engineering- or science-qualified staff[1][2].
The company serves pharmaceutical firms and other industries needing IT, operational technology, and scientific expertise to enhance efficiency, compliance, data utilization, productivity, and risk reduction. Its growth is evidenced by a proactive, continuous-improvement model that modernizes operations while ensuring uptime and regulatory adherence[1][2].
(Note: A separate entity, west~bourne at westbourne.com, is a consumer packaged goods brand focused on regenerative agriculture products, not a technology company[3][4]. Another, WESTBOURNE TECHNOLOGIES LTD, appears in UK records but lacks detailed public info[5]. This overview centers on the primary technology match, Westbourne IT.)
Westbourne IT Global Services has over 30 years of client engagement, evolving into a trans-global provider with operations in Ireland (phone: +353 214314310), New Zealand (HQ at 144 Beaumont St, Auckland), and the USA[1][2]. While specific founding details and key partners are not publicly detailed in available sources, its longevity underscores a steady expansion from core IT support to specialized pharma solutions, blending technology and science[1]. This trajectory reflects adaptation to industry demands, particularly in regulated sectors like pharmaceuticals, where it has built expertise in digital transformation and validation[1].
Westbourne rides the wave of pharma digital transformation, where market forces like regulatory pressures (e.g., compliance optimization), data-driven efficiency, and operational agility demand integrated IT-science solutions. Timing aligns with industry shifts toward modernizing labs/manufacturing amid rising complexities in biotech/pharma, where validation and risk reduction are critical[1]. It influences the ecosystem by enabling "better for planet" outcomes indirectly through efficient, low-risk tech support, while its global model supports startup-like agility in established pharma operations, fostering productivity in a sector accounting for significant tech spend[1][2].
Westbourne is poised to expand in pharma's digital pivot, leveraging its 30+ years and global ops to capture demand for AI-enhanced validation, sustainable IT, and hybrid tech-science services. Trends like stricter regulations, cloud validation (CSA), and ValGenesis integrations will shape its path, potentially growing revenue beyond $21M via partnerships and new regions. Its influence may evolve toward leading "regenerative" tech ecosystems in pharma—optimizing today while modernizing for tomorrow—cementing its role as a reliable backbone for industry innovation[1][2].
West Bourne has raised $530K across 1 funding round. Most recently, it raised $530K Seed in September 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2022 | $530K Seed | SOSV |